Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study

Blood (2022) 140 (Supplement 1): 7317–7319.

https://doi.org/10.1182/blood-2022-157302

Published: 2022

Journal Articles

Persistence of Monoclonal Gammopathies in Serial Samples from a US Population-Based Screening Study

Habib El-Khoury, Luca Bertamini, Jean-Baptiste Alberge, David J. Lee, Ciara Murphy, Grace Fleming, Christian J. Cea-Curry, Maya I. Davis, Jacqueline Perry, Elizabeth D. Lightbody, Dhananjay Sakrikar, Derek Troske, David Barnidge, Mark C. Perkins, Stephen Harding, Gad Getz, Catherine R. Marinac, Irene Ghobrial

Blood (2022) 140 (Supplement 1): 10101–10103.

https://doi.org/10.1182/blood-2022-169380

Published: 2022

Journal Articles

Abnormal Free Light Chains in Individuals with African Ancestry Screened for Monoclonal Gammopathy: Definition of New Reference Range Accounting for Renal Function and Race

Blood (2022) 140 (Supplement 1): 10005–10006.

https://doi.org/10.1182/blood-2022-164436

Published: 2022

Journal Articles

Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM

Blood (2022) 140 (Supplement 1): 7158–7159.

https://doi.org/10.1182/blood-2022-167212

Published: 2022

Journal Articles

Monitoring Plasma Cells and Clonal Emergence through Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma

Blood (2022) 140 (Supplement 1): 9927–9928.

https://doi.org/10.1182/blood-2022-169034

Published: 2022

Journal Articles

Single-Cell RNA-Sequencing of 245 Tumor Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveals Novel Insights into Malignant Plasma Cell Biology

Blood (2022) 140 (Supplement 1): 254–255.

https://doi.org/10.1182/blood-2022-167325

Published: 2022

Journal Articles

Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Progression in Patients with High-Risk Smoldering Multiple Myeloma Treated with Immunotherapy

Romanos Sklavenitis-Pistofidis, Michelle P. Aranha, Nicholas J. Haradhvala, Shohreh Varmeh, Daniel Heilpern-Mallory, Ting Wu, Nang Kham Su, Elizabeth D. Lightbody, François Aguet, Oksana Zavidij, Sabrin Tahri, Tarek H. Mouhieddine, Gad Getz, Irene Ghobrial

Blood (2022) 140 (Supplement 1): 268–269.

https://doi.org/10.1182/blood-2022-168839

Published: 2022

Journal Articles

High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients

Blood (2022) 140 (Supplement 1): 4303–4304.

https://doi.org/10.1182/blood-2022-170346

Published: 2022

Journal Articles

Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation

Blood (2022) 140 (Supplement 1): 602–603.

https://doi.org/10.1182/blood-2022-162851

Published: 2022

Journal Articles

Reconstructing the Genomic History of Multiple Myeloma Precursor Disease: Novel Insights and Clinical Applicability

Blood (2022) 140 (Supplement 1): 4257–4258.

https://doi.org/10.1182/blood-2022-167041

Published: 2022

Journal Articles

Single-Cell RNA-Sequencing of 370 Bone Marrow and Peripheral Blood Immune Cell Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveal Significant Immune Dysregulation at the MGUS Stage, and Novel Interactions between Tumor and Immune Cells

Romanos Sklavenitis-Pistofidis, Ting Wu, Mahshid Rahmat, Yoshinobu Konishi, Elizabeth D. Lightbody, Michael Timonian, Junko Tsuji, Danielle T. Firer, Nicholas J. Haradhvala, Cinnie Yentia Soekojo, Xiyue Wang, Daniel Heilpern-Mallory, François Aguet, Gad Getz, Irene Ghobrial

Blood (2022) 140 (Supplement 1): 860–861.

https://doi.org/10.1182/blood-2022-168911

Published: 2022

Journal Articles

In Situ Characterization of Chromatin Landscape in Progression of Smoldering Precursor Stage to Multiple Myeloma

Mahshid Rahmat, Michael Vinyard, Romanos Sklavenitis-Pistofidis, Kendell Clement, Elizabeth D. Lightbody, Cody J. Boehner, Laura Hevenor, Jacqueline Perry, Gad Getz, Irene Ghobrial

Blood (2022) 140 (Supplement 1): 4222–4223.

https://doi.org/10.1182/blood-2022-167727

Published: 2022

Journal Articles

Prevalence of Monoclonal Gammopathies Detected By Mass Spectrometry and Their Risk Factors Among Black Africans in South Africa

Blood (2022) 140 (Supplement 1): 7228–7229.

https://doi.org/10.1182/blood-2022-167268

Published: 2022

Journal Articles

Inhibition of MICA and MICB Shedding Enhances Cytokine-Induced Memory-like NK Cell-Mediated Activity Against Multiple Myeloma

Blood (2022) 140 (Supplement 1): 4204–4206.

https://doi.org/10.1182/blood-2022-164811

Published: 2022

Journal Articles

Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenström Macroglobulinemia (WM)

David S. Siegel, MD PhD, Jonathan L. Kaufman, MD, Noopur S. Raje, MD, Joseph R. Mikhael, MD, Prashant Kapoor, MD, Steven P. Treon, MD PhD, Jorge J. Castillo, MD, Linda L. Neuman, MD MBA, Ju RueyJiuan Lee, PhD, Irene Ghobrial, MD

Blood (2014) 124 (21): 1715.

https://doi.org/10.1182/blood.V124.21.1715.1715

Published: 2014

Journal Articles

Let-7 Microrna Family Members Regulate Cell Proliferation in Multiple Myeloma

Salomon Manier, MD, Antonio Sacco, BS, Patricia Maiso, PhD, Yong Zhang, PhD, Yang Liu, PhD, Yosra Aljawai, BS, Weixin Wang, PhD, Meghan Corrigan-Cummins, Xavier Leleu, MD, PhD, Katherine R. Calvo, MD, PhD, Ola Landgren, M.D., Ph.D., Aldo M. Roccaro, MD, PhD, Irene Ghobrial, MD

Blood (2012) 120 (21): 570.

https://doi.org/10.1182/blood.V120.21.570.570

Published: 2012

Journal Articles

Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up

Blood (2010) 116 (21): 3049.

https://doi.org/10.1182/blood.V116.21.3049.3049

Published: 2010

Journal Articles

Proteomic Studies Identify Citron Rho Interacting Kinase (CRIK), a Novel Protein That Regulates Proliferation and Survival In Multiple Myeloma Cells

Hai T Ngo, Aldo M. Roccaro, MD, PhD, Alexey Leontovich, Yang Liu, PhD, Yong Zhang, PhD, Abdel Kareem A. Azab, PhD, BSPharm, Antonio Sacco, Eric Still, Brittany Morgan, Kenneth C. Anderson, Irene Ghobrial, MD

Blood (2010) 116 (21): 2958.

https://doi.org/10.1182/blood.V116.21.2958.2958

Published: 2010

Journal Articles

The Role of Serum Immunoglobulin Free Light Chain In Response and Progression In Waldenstrom Macroglobulinemia

Xavier Leleu, MD, PhD, Wanling Xie, MS, Meghan Rourke, Ranjit Banwait, Renee Leduc, Nitin Roper, Edie Weller, Irene Ghobrial, MD

Blood (2010) 116 (21): 3095.

https://doi.org/10.1182/blood.V116.21.3095.3095

Published: 2010

Journal Articles

Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple Myeloma

Irene Ghobrial, MD, Abdel Kareem A. Azab, PhD, BSPharm, Jacob P. Laubach, MD, MPP, Ranjit Banwait, Meghan Rourke, Phong Quang, Nikhil C. Munshi, MD, Robert L. Schlossman, MD, Stacey Chuma, BSN, Janet Kunsman, NP, Diane Warren, Amy Sam, Eric Still, Brittany Morgan, Kenneth C. Anderson, Paul G Richardson

Blood (2010) 116 (21): 1943.

https://doi.org/10.1182/blood.V116.21.1943.1943

Published: 2010

NARROW

Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study

Persistence of Monoclonal Gammopathies in Serial Samples from a US Population-Based Screening Study

Abnormal Free Light Chains in Individuals with African Ancestry Screened for Monoclonal Gammopathy: Definition of New Reference Range Accounting for Renal Function and Race

Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM

Monitoring Plasma Cells and Clonal Emergence through Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma

Single-Cell RNA-Sequencing of 245 Tumor Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveals Novel Insights into Malignant Plasma Cell Biology

Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Progression in Patients with High-Risk Smoldering Multiple Myeloma Treated with Immunotherapy

High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients

Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation

Reconstructing the Genomic History of Multiple Myeloma Precursor Disease: Novel Insights and Clinical Applicability

Single-Cell RNA-Sequencing of 370 Bone Marrow and Peripheral Blood Immune Cell Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveal Significant Immune Dysregulation at the MGUS Stage, and Novel Interactions between Tumor and Immune Cells

In Situ Characterization of Chromatin Landscape in Progression of Smoldering Precursor Stage to Multiple Myeloma

Prevalence of Monoclonal Gammopathies Detected By Mass Spectrometry and Their Risk Factors Among Black Africans in South Africa

Inhibition of MICA and MICB Shedding Enhances Cytokine-Induced Memory-like NK Cell-Mediated Activity Against Multiple Myeloma

Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenström Macroglobulinemia (WM)

Let-7 Microrna Family Members Regulate Cell Proliferation in Multiple Myeloma

Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up

Proteomic Studies Identify Citron Rho Interacting Kinase (CRIK), a Novel Protein That Regulates Proliferation and Survival In Multiple Myeloma Cells

The Role of Serum Immunoglobulin Free Light Chain In Response and Progression In Waldenstrom Macroglobulinemia

Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only